FDA approves Alzheimer’s treatment LEQEMBI
Eisai and Biogen have announced that the FDA has approved LEQEMBI 100 mg/mL injection for intravenous use for treating Alzheimer's disease.| Labiotech.eu
Eisai and Biogen have announced that the FDA has approved LEQEMBI 100 mg/mL injection for intravenous use for treating Alzheimer's disease.| Labiotech.eu
Get the latest news related to Alzheimer's, including the latest research, partnerships, and technology advancements of alzheimer's biotech companies.| Labiotech.eu
The FDA approved Leqembi (lecanemab-irmb), the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiol| U.S. Food and Drug Administration
Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following the Food and Drug Administration’s (FDA) move to grant traditional approval to the drug that treats individuals with Alzheimer’s disease. The Centers for Medicare & Medicaid Services had previously announced this would be the case and released more details on coverage today.| www.cms.gov
How many people have dementia worldwide? Are the numbers increasing? What is the cost of dementia care?| www.alzint.org
